Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171348 | 0.89 | NR1I2 (0.64) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL14546539 | 0.83 | NR1I2 (0.55) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL14608693 | 0.81 | NR1I2 (0.53) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL5195427 | 0.80 | F2 (0.43) | NR1I2CTSVCTSLMAOA | |
| SCHEMBL13399696 | 0.80 | CTSV (0.59) | CTSVCTSLMAOA | |
| SCHEMBL14608490 | 0.78 | NR1I2 (0.50) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL12966419 | 0.77 | NR1I2 (0.60) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL12966402 | 0.76 | CTSV (0.51) | NR1I2CTSVCTSLCYP2D6CYP2C9 | |
| SCHEMBL16790723 | 0.76 | GABRP (0.61) | CTSVCTSLCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5193548 | 0.75 | PPARG (0.54) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118058-B9 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2012-03-28 | — | — | EP | disclosed |
| EP-2118058-B1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA K.S. (CZ) | 2010-04-08 | — | — | US | disclosed |
| WO-2008098527-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA A.S. (CZ) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | CYP19A1, CYP17A1, SHBG | NR1I2 695/4885CTSV 4847/4885CTSL 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.